India’s weight-loss price war begins as semaglutide patent expires
Story summaryGeneric slimming drugs are expected to flood a market where one in four adults are currently either overweight or obese
Read at South China Morning PostOpens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.